| NCT05705453 | Epidural Stimulation After Neurologic Damage: Long-Term Outcomes | University of Minnesota | | - Age ≥ 22 yrs
- Level C5-S5
AIS A, B- ≥ 1 years
- HAVE an existing and functional implanted spinal cord stimulator system that is FDA approved
- NOT have current or anticipated need for opioid pain medication preventing participation in the rehabilitation program
- NOT have received Botox injections in the last six months
| Recruiting | 50 | NA | Technology | Arm/hand function | - Surface Electromyography (sEMG)
| 10 years | 01 March 2023 | 30 January 2023 | 1 | |
| NCT03898804 | An Early Feasibility Study of the ReHAB System | University Hospitals Cleveland Medical Center | Single Group Assignment | - Age 22 - 65 yrs
- Level C1-C8
AIS - ≥ 12 months
- Be at least 12 months post onset of tetraplegia.
- Not have an implanted stimulator (e.g. pacemaker or stimulators (of the spinal cord, deep brain, vagus nerve), cochlear implant, or defibrillator.
- Not be ventilator dependent.
| Recruiting | 12 | Not Applicable | Technology | General health | - Grasp and Release Test (GRT)
- Lawton Instrumental Activities of Daily Living scale (IADL)
| 13 months | 09 April 2019 | 02 April 2019 | 1 | |
| NCT05601661 | Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord Injury | The University of Texas Health Science Center, Houston | | - Age ≥ 18 yrs
- Level C1-C8
AIS B, C, D- ≥ 12 months
- NOT have prior history of vagus nerve injury
| Ended | 6 | NA | Technology | Arm/hand function | - Capabilities of Upper Extremity Instrument (CUE- Q and CUE-T)
- Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP)
- Spinal Cord Independence Measure (SCIM)
- Toronto Rehabilitation Institute Hand Function Test
| 132 days after enrollment | 15 June 2023 | 01 November 2022 | 1 | |
| NCT05635851 | NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI | Simon Fraser University | | - Age 19 - 80 yrs
- Level C1-S5
AIS - ≥ 1 years
- Have known incidence of autonomic dysreflexia.
| Recruiting soon | 26 | PHASE2 | Drug | General health | | during testing | 01 September 2025 | 02 December 2022 | 0 | |
| NCT05639946 | Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | University of Minnesota | | - Age ≥ 18 yrs
- Level C1-S5
AIS - ≥ 3 months
- have completed inpatient rehab
| Ended | 44 | PHASE3 | Drug | Pain | - International Spinal Cord Injury Pain Classification (ISCIP)
| 3 months | 01 January 2023 | 07 December 2022 | 1 | |
| NCT05550987 | The Use of Modern Technologies in Neurorehabilitation | University of Rzeszow | Parallel Assignment | - Age 18 - 75 yrs
- Level C1-S5
AIS - All
- NOT have bone density t-score of less than -2.5
| Recruiting soon | 120 | Not Applicable | Rehabilitation | Standing/walking/mobility | - 10 Meter Walking Test (10 MWT)
- 2 Minute Walk Test
- Barthel Index (BI)
- Berg Balance Scale (BBS)
- Box and Block Test (BBT)
- Frenchay Activities Index (FAI)
- Tardieu Scale
- Timed Up and Go Test (TUG)
- World Health Organization Disability Assessment Schedule II (WHODAS 2.0)
- World Health Organization Quality of Life- BREF (WHOQOL-BREF)
| immediately after intervention | 01 November 2022 | 22 September 2022 | 0 | |
